Papillomavirus Virion Proteins and Vaccines

$530,145ZIAFY2025CANIH

Division Of Basic Sciences - Nci

Investigators

Linked publications, trials & patents

Paper 38793767 Paper 38624210 Paper 38437560 Paper 37040086 Paper 36620882 Paper 36423642 Paper 35749366 Paper 35709811 Paper 35700704 Paper 35640980 Paper 35351898 Paper 35285688 Paper 34857420 Paper 33200359 Paper 32502860 Paper 32091596 Paper 32091594 Paper 29366703 Paper 29208378 Paper 29159802 Paper 28954299 Paper 28876435 Paper 28497074 Paper 28402946 Paper 28250129 Paper 27653561 Paper 27281415 Paper 27265849 Paper 27174913 Paper 27043262 Paper 27013720 Paper 26892991 Paper 26727228 Paper 26467666 Paper 26317490 Paper 25452387 Paper 23571174 Paper 23536682 Paper 23345514 Paper 23143305 Paper 23123024 Paper 23010077 Paper 22985477 Paper 22961341 Paper 22867718 Paper 22850119 Paper 22593236 Paper 22586631 Paper 22219162 Paper 21934576 Paper 21865087 Paper 21483020 Paper 21430072 Paper 21422431 Paper 21402543 Paper 21241731 Paper 20833377 Paper 20530315 Paper 20420520 Paper 19920181 Paper 19519255 Paper 19470949 Paper 19155521 Paper 19078983 Paper 19073722 Paper 18980286 Paper 18847562 Paper 18829767 Paper 18798536 Paper 18640170 Paper 18541349 Paper 18446086 Paper 18367526 Paper 18305047 Paper 18032596 Paper 17699008 Paper 17603495 Paper 17553881 Paper 16839203 Paper 16670757 Paper 16432216 Paper 16432208 Paper 16350417 Paper 15882523 Paper 15832296 Paper 15709003 Paper 15383670 Paper 15135592 Paper 15051381 Paper 15047820 Paper 14694107 Paper 12902442 Paper 12807954 Paper 12706410 Paper 12667809 Patent 9388221 Patent 8999290 Patent 8404244 Patent 8394411

Abstract

The main new finding is that in a large non-inferiority HPV vaccine trial, the 5-year efficacy of one dose of either of two FDA-approved vaccines is not inferior to the efficacy of two doses and is 97% or higher. These result validate our hypothesis that this would be the case. This is the first time that a single dose of a preventive subunit vaccine has been found to be non-inferior to two doses. The high efficacy is probably attributable to the repetitive nature of the virus-like particles immunogen.

View original record on NIH RePORTER →